Evidence map›Paper›PMID 41634482›Full record

ArticleOphthalmology and therapy2026

One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

Gabriela Grimaldi, Nicolò Bartolomeo, Justus G Garweg, Isabel B Pfister, Christin Schild, Arianna Peyla, Anne Tillmann, Eva Cristina De Oliveira Figueiredo, Tahm Spitznagel, Alice M Kitay and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Eighteen-month real-world outcomes of intravitreal aflibercept 8 mg in treatment-naïve neovascular age-related macular degeneration: a UK single-centre experience.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Gabriela Grimaldi *Department of Ophthalmology, Institute of Clinical Neurosciences of Southern Switzerland (INSI), Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland. gabriela.grimaldi@eoc.ch.ORCID http://orcid.org/0000-0003-2435-7867
Nicolò Bartolomeo *Swiss Visio Retina Research Center, Lausanne, Switzerland.
Justus G GarwegBerner Augenklinik and Swiss Eye Institute, Bern, Switzerland.
Isabel B PfisterBerner Augenklinik and Swiss Eye Institute, Bern, Switzerland.
Christin SchildBerner Augenklinik and Swiss Eye Institute, Bern, Switzerland.
Arianna PeylaDepartment of Ophthalmology, Institute of Clinical Neurosciences of Southern Switzerland (INSI), Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland.
Anne TillmannAugenarztpraxisgemeinschaft Gutblick AG, Zurich, Switzerland.
Eva Cristina De Oliveira FigueiredoDepartment of Ophthalmology, Jules-Gonin Eye Hospital, Fondation Asile Des Aveugles, University of Lausanne, Lausanne, Switzerland.
Tahm SpitznagelDepartment of Ophthalmology, Stadtspital Triemli, Zurich, Switzerland.
Alice M KitayTalacker Augen Zentrum Zürich (TAZZ), Zurich, Switzerland.
Felix GabathulerDepartment of Ophthalmology, University Hospital, Zurich, Switzerland.
Sandrine ZweifelDepartment of Ophthalmology, University Hospital, Zurich, Switzerland.
Malaika Mihal Kurz-LevinTalacker Augen Zentrum Zürich (TAZZ), Zurich, Switzerland.
Andreas EbneterDepartment of Ophthalmology, Kantonsspital St. Gallen, University of Bern, Bern, Switzerland.
Gábor Márk SomfaiDepartment of Ophthalmology, Stadtspital Triemli, Zurich, Switzerland.
Chiara M EandiDepartment of Ophthalmology, Jules-Gonin Eye Hospital, Fondation Asile Des Aveugles, University of Lausanne, Lausanne, Switzerland.
Marion R MunkAugenarztpraxisgemeinschaft Gutblick AG, Zurich, Switzerland.
Aude Ambresin *Swiss Visio Retina Research Center, Lausanne, Switzerland.
Moreno Menghini *Department of Ophthalmology, Institute of Clinical Neurosciences of Southern Switzerland (INSI), Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis study reports the 1-year efficacy of aflibercept 8 mg (afl8) in a real-world cohort of treatment-naïve patients with neovascular age-related macular degeneration (nAMD).

methodsAn observational, retrospective case series from nine centers of the Swiss Retina Research Network including treatment-naïve eyes with nAMD started on intravitreal afl8. Changes in visual acuity (VA), macular thickness, pigment epithelial detachment (PED) height, and retinal fluids were evaluated over 12 months and compared with baseline. Treatment intervals and safety data were recorded along with subgroup analyses based on macular neovascularization type, loading-phase completion, and treatment regimen.

resultsA total of 91 eyes met the inclusion criteria. After 1 year of treatment, VA changed by + 1.0 ± 13.2 letters (p = 0.018), mean CST changed by -110.0 ± 130.9 µm (p < 0.001), and mean PED height changed by -71.2 ± 104.8 µm (p < 0.001). After 12 months, 66.2% of eyes demonstrated a complete absence of macular fluids. Mean treatment interval was 13.9 ± 7.9 weeks, with 56.1% of eyes being extended to ≥ 12 weeks with an anatomy-driven approach. No functional or anatomical differences were observed between eyes receiving a clean loading phase and in terms of different macular neovascularization (MNV) subtypes. Two adverse events were observed.

conclusionsThe first 1-year real-world experience with afl8 in patients with nAMD revealed a robust anatomical response but only a variable and limited visual gain over 12 months due to a ceiling effect. Our findings confirm the fast and sustained macular drying reported from clinical trials, allowing for extended treatment intervals without compromising safety and efficacy.

Indexed as

AfliberceptAflibercept 8 mgAge-related macular degenerationAnti-VEGFIntravitreal injectionMacular neovascularizationTreat and extend

Identifiers

PMID41634482
PMCPMC12976334

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.